377 related articles for article (PubMed ID: 11428477)
1. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
PRIME CARE Study Investigators Group
Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
[TBL] [Abstract][Full Text] [Related]
3. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
White HD
J Invasive Cardiol; 2000 Feb; 12 Suppl A():6A-13A. PubMed ID: 10731290
[TBL] [Abstract][Full Text] [Related]
5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Godoy I; Herrera C; Zapata C; Kunstmann S; Abufhele A; Corbalán R
Rev Med Chil; 1998 Mar; 126(3):259-64. PubMed ID: 9674294
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction.
Cohen M
Semin Thromb Hemost; 1999; 25 Suppl 3():113-21. PubMed ID: 10549726
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
De Luca G; Marino P
Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparins better than unfractionated heparin in unstable coronary artery disease? Unstable angina pectoris/non-Q wave infarction a partly outpatient clinic condition?
Kauw FH; Cleophas TJ; Kalmansohn RB
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):392-7. PubMed ID: 9707355
[TBL] [Abstract][Full Text] [Related]
11. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins in the treatment of unstable angina.
Ageno W; Turpie AG
Minerva Cardioangiol; 2002 Dec; 50(6):643-51. PubMed ID: 12473984
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
[TBL] [Abstract][Full Text] [Related]
15. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H
Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147
[TBL] [Abstract][Full Text] [Related]
16. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
Demers C
Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
Antman EM; Cohen M; McCabe C; Goodman SG; Murphy SA; Braunwald E;
Eur Heart J; 2002 Feb; 23(4):308-14. PubMed ID: 11812067
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
[TBL] [Abstract][Full Text] [Related]
19. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
